Recent clinical findings show that VERVE-102, an innovative in vivo base editing medication, successfully lowers LDL cholesterol by permanently deactivating the PCSK9 gene in the liver. Data from the Heart-2 trial indicates that a single infusion can reduce harmful cholesterol levels by as much as 62%, with results remaining stable for up to 18 months. This genetic medicine approach mimics naturally occurring protective mutations to offer a potential one-time treatment for patients with hypercholesterolemia who currently rely on chronic daily or monthly therapies. Additionally, the FDA has introduced a "plausible mechanism" regulatory pathway to expedite the approval of such ultra-rare disease and targeted genetic treatments. Beyond the liver, researchers are expanding base editing and epigenetic editing technologies to address diverse conditions ...